CL2025001949A1 - Formulaciones líquidas orales de netupitant y palonosetrón - Google Patents

Formulaciones líquidas orales de netupitant y palonosetrón

Info

Publication number
CL2025001949A1
CL2025001949A1 CL2025001949A CL2025001949A CL2025001949A1 CL 2025001949 A1 CL2025001949 A1 CL 2025001949A1 CL 2025001949 A CL2025001949 A CL 2025001949A CL 2025001949 A CL2025001949 A CL 2025001949A CL 2025001949 A1 CL2025001949 A1 CL 2025001949A1
Authority
CL
Chile
Prior art keywords
netupitant
palonosetron
oral formulations
liquid oral
efficacy
Prior art date
Application number
CL2025001949A
Other languages
English (en)
Inventor
Parisi Davide
Frizzarin Stefano
Fabiani Flavio
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of CL2025001949A1 publication Critical patent/CL2025001949A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones líquidas de netupitant y palonosetrón administradas por vía oral, que son eficaces, químicamente estables y fisiológicamente equilibradas para garantizar su inocuidad y eficacia.
CL2025001949A 2023-01-03 2025-06-30 Formulaciones líquidas orales de netupitant y palonosetrón CL2025001949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363436713P 2023-01-03 2023-01-03

Publications (1)

Publication Number Publication Date
CL2025001949A1 true CL2025001949A1 (es) 2025-10-10

Family

ID=89663494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001949A CL2025001949A1 (es) 2023-01-03 2025-06-30 Formulaciones líquidas orales de netupitant y palonosetrón

Country Status (12)

Country Link
US (1) US20250345270A1 (es)
EP (1) EP4615413B1 (es)
JP (1) JP2026503256A (es)
KR (1) KR20250121611A (es)
CN (1) CN120500326A (es)
AU (1) AU2023421785A1 (es)
CL (1) CL2025001949A1 (es)
CO (1) CO2025008629A2 (es)
IL (1) IL321814A (es)
MX (1) MX2025007736A (es)
TW (1) TW202428273A (es)
WO (1) WO2024147073A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276080T3 (es) 2002-02-08 2007-06-16 THE PROCTER & GAMBLE COMPANY Bolsita a prueba de niños.
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
EP2722045B1 (en) * 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
ES2579616T3 (es) 2011-10-18 2016-08-12 Helsinn Healthcare Sa Combinaciones terapéuticas de netupitant y palonosetrón
CA2930177A1 (en) 2013-11-27 2015-06-04 Johnson & Johnson Consumer Inc. Stick pack pouch packaging
US20230310465A1 (en) * 2020-08-18 2023-10-05 Leiutis Pharmaceuticals Llp Nano lipid carrier system for improving permeation of active ingredients

Also Published As

Publication number Publication date
CO2025008629A2 (es) 2025-07-17
MX2025007736A (es) 2025-08-01
KR20250121611A (ko) 2025-08-12
EP4615413B1 (en) 2026-04-08
JP2026503256A (ja) 2026-01-28
CN120500326A (zh) 2025-08-15
WO2024147073A1 (en) 2024-07-11
AU2023421785A1 (en) 2025-06-05
EP4615413A1 (en) 2025-09-17
TW202428273A (zh) 2024-07-16
IL321814A (en) 2025-08-01
US20250345270A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
CU20190005A7 (es) Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico
JOP20170135A1 (ar) مركبات ديازاسبيروألكيل مثيل-إندول
EA202090573A1 (ru) Составы нирапариба
EA201992162A1 (ru) Составы на основе нирапариба
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR122059A1 (es) Usos y formulaciones de cannabinoides
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
NO20071485L (no) Kjemiske substanser.
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
CR20120432A (es) Formulaciones farmacéuticas sólidas de ramipril y besilato de amlodipino y su preparación
JOP20250311A1 (ar) مثبطات tyk2 وتركيبات وطرق لها
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CL2025001949A1 (es) Formulaciones líquidas orales de netupitant y palonosetrón
MX2020010747A (es) Formulaciones topicas que comprenden estroncio y metilsulfonilmetano (msm) y metodos de tratamiento.
CO2024014215A2 (es) Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
CO2024004886A2 (es) Composiciones de gel inmunógenas